JP2020531002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531002A5 JP2020531002A5 JP2020507675A JP2020507675A JP2020531002A5 JP 2020531002 A5 JP2020531002 A5 JP 2020531002A5 JP 2020507675 A JP2020507675 A JP 2020507675A JP 2020507675 A JP2020507675 A JP 2020507675A JP 2020531002 A5 JP2020531002 A5 JP 2020531002A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- amino acid
- igg
- acid substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920001184 polypeptide Polymers 0.000 claims 120
- 108090000765 processed proteins & peptides Proteins 0.000 claims 120
- 102000004196 processed proteins & peptides Human genes 0.000 claims 120
- 150000001413 amino acids Chemical group 0.000 claims 76
- 235000001014 amino acid Nutrition 0.000 claims 68
- 238000006467 substitution reaction Methods 0.000 claims 62
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 18
- 235000018102 proteins Nutrition 0.000 claims 15
- 102000004169 proteins and genes Human genes 0.000 claims 15
- 108090000623 proteins and genes Proteins 0.000 claims 15
- 235000004279 alanine Nutrition 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 11
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 11
- 239000004473 Threonine Substances 0.000 claims 11
- 241000283073 Equus caballus Species 0.000 claims 9
- 241001465754 Metazoa Species 0.000 claims 9
- 239000000833 heterodimer Substances 0.000 claims 9
- 241000282326 Felis catus Species 0.000 claims 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 8
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 8
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 8
- 241000282465 Canis Species 0.000 claims 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 7
- 239000004471 Glycine Substances 0.000 claims 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 6
- 229940024606 amino acid Drugs 0.000 claims 6
- 235000018417 cysteine Nutrition 0.000 claims 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 5
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 5
- 239000004475 Arginine Substances 0.000 claims 4
- 241000282324 Felis Species 0.000 claims 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical group C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 4
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 4
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 4
- 238000007913 intrathecal administration Methods 0.000 claims 4
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 241000282472 Canis lupus familiaris Species 0.000 claims 3
- 229960000310 isoleucine Drugs 0.000 claims 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 3
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 241000282327 Felis silvestris Species 0.000 claims 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims 2
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 2
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical group CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 2
- 238000012575 bio-layer interferometry Methods 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 238000001361 intraarterial administration Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 239000004474 valine Chemical group 0.000 claims 2
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- 241000283086 Equidae Species 0.000 claims 1
- 102000051325 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- 102100040918 Pro-glucagon Human genes 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 229960001230 asparagine Drugs 0.000 claims 1
- 235000009582 asparagine Nutrition 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000007919 intrasynovial administration Methods 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025188214A JP2026048634A (ja) | 2017-08-15 | 2025-11-07 | 獣医学用ｉｇｇ ｆｃ変異体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762545858P | 2017-08-15 | 2017-08-15 | |
| US62/545,858 | 2017-08-15 | ||
| PCT/IB2018/056142 WO2019035010A1 (en) | 2017-08-15 | 2018-08-15 | IGG VARIANTS FOR VETERINARY USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025188214A Division JP2026048634A (ja) | 2017-08-15 | 2025-11-07 | 獣医学用ｉｇｇ ｆｃ変異体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020531002A JP2020531002A (ja) | 2020-11-05 |
| JP2020531002A5 true JP2020531002A5 (cg-RX-API-DMAC10.html) | 2021-09-30 |
Family
ID=65361820
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507675A Pending JP2020531002A (ja) | 2017-08-15 | 2018-08-15 | 獣医学用ｉｇｇ ｆｃ変異体 |
| JP2025188214A Pending JP2026048634A (ja) | 2017-08-15 | 2025-11-07 | 獣医学用ｉｇｇ ｆｃ変異体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025188214A Pending JP2026048634A (ja) | 2017-08-15 | 2025-11-07 | 獣医学用ｉｇｇ ｆｃ変異体 |
Country Status (10)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3939605A1 (en) | 2016-12-09 | 2022-01-19 | Akston Biosciences Corporation | Insulin-fc fusions and methods of use |
| AU2018318440A1 (en) | 2017-08-15 | 2020-02-13 | Kindred Biosciences, Inc. | IgG Fc variants for veterinary use |
| HUE062719T2 (hu) | 2018-06-29 | 2023-11-28 | Akston Biosciences Corp | Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások |
| US11267862B2 (en) | 2018-06-29 | 2022-03-08 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| EP3866842A4 (en) * | 2018-10-18 | 2022-07-13 | Kindred Biosciences, Inc. | FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE |
| WO2020139984A1 (en) * | 2018-12-27 | 2020-07-02 | Kindred Biosciences, Inc. | Igg fc variants for veterinary use |
| CN120005022A (zh) * | 2019-01-03 | 2025-05-16 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物及使用方法 |
| KR20220066002A (ko) * | 2019-03-20 | 2022-05-23 | 킨드레드 바이오사이언시스, 인코포레이티드 | 의학적 용도의 ngf 길항제 |
| JP2022542275A (ja) * | 2019-07-30 | 2022-09-30 | キンドレッド バイオサイエンシズ インコーポレイテッド | 動物用パルボウイルス抗体 |
| KR102865175B1 (ko) | 2019-12-19 | 2025-09-30 | 악스톤 바이오사이언시스 코퍼레이션 | 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법 |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| CN115135669B (zh) | 2020-02-19 | 2026-05-19 | 硕腾服务有限责任公司 | 修饰的Fc区 |
| US20240067738A1 (en) * | 2020-03-18 | 2024-02-29 | Elanco Us Inc. | Anti-il4 receptor antibodies for veterinary use |
| US11192930B2 (en) | 2020-04-10 | 2021-12-07 | Askton Bioscences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| LT3972987T (lt) | 2020-04-10 | 2023-09-25 | Akston Biosciences Corporation | Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai |
| CA3173864A1 (en) * | 2020-04-22 | 2021-10-28 | Shyr Jiann Li | Long-acting anti-il31 antibodies for veterinary use |
| GB202005879D0 (en) * | 2020-04-22 | 2020-06-03 | Petmedix Ltd | Heterodimeric proteins |
| US11198719B2 (en) | 2020-04-29 | 2021-12-14 | Akston Biosciences Corporation | Ultra-long acting insulin-Fc fusion protein and methods of use |
| JP7832123B2 (ja) | 2020-05-11 | 2026-03-17 | インベテックス インコーポレイテッド | 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法 |
| CN116096741B (zh) | 2020-07-10 | 2024-10-18 | 因外泰克斯公司 | 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法 |
| EP4199942A4 (en) * | 2020-08-24 | 2025-03-19 | The Trustees of The University of Pennsylvania | Viral vector encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases in felines |
| CN112625093B (zh) * | 2020-12-29 | 2022-12-23 | 清远市图微安创科技开发有限公司 | 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物 |
| US11667689B2 (en) | 2021-07-23 | 2023-06-06 | Akston Biosciences Corporation | Insulin-Fc fusion proteins and methods of use to treat cancer |
| EP4380974A1 (en) * | 2021-08-06 | 2024-06-12 | Petmedix Ltd. | Antibody fc variants |
| AU2023415535A1 (en) | 2022-12-27 | 2025-07-10 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| CN121002059A (zh) | 2023-01-20 | 2025-11-21 | 因外泰克斯公司 | 用于伴侣动物的双特异性结合剂 |
| GB202311984D0 (en) * | 2023-08-04 | 2023-09-20 | Petmedix Ltd | Optimised fc molecules |
| WO2025166165A1 (en) * | 2024-02-01 | 2025-08-07 | Zoetis Services, Llc | Compositions and methods for modifying antibody effector functions |
| WO2026039359A1 (en) * | 2024-08-12 | 2026-02-19 | Akston Biosciences Corporation | Fc fusion protein therapeutics for companion animal obesity and methods of use |
| WO2026038455A1 (ja) * | 2024-08-14 | 2026-02-19 | 国立大学法人山口大学 | 細胞傷害活性及び細胞貪食活性を低減させた抗ネコ抗体 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6207383B1 (en) * | 1998-07-27 | 2001-03-27 | University Of Utah Research Foundation | Mutations in and genomic structure of HERG—a long QT syndrome gene |
| US7297482B2 (en) * | 1998-10-08 | 2007-11-20 | Rigel Pharmaceuticals, Inc. | Structurally biased random peptide libraries based on different scaffolds |
| AU2511901A (en) * | 1999-12-23 | 2001-07-09 | Universite De Geneve | Basolateral sorting signal and inhibitors thereof |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| JP2004321100A (ja) | 2003-04-25 | 2004-11-18 | Rikogaku Shinkokai | ＩｇＧのＦｃ領域を含むタンパク質の変異体 |
| ES2371072T3 (es) | 2003-06-12 | 2011-12-27 | Eli Lilly And Company | Proteínas de fusión análogas de glp-1. |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP2008525452A (ja) | 2004-12-22 | 2008-07-17 | イーライ リリー アンド カンパニー | Ｇｌｐ−１類似体融合蛋白質製剤 |
| US20110123440A1 (en) * | 2005-03-29 | 2011-05-26 | Genevieve Hansen | Altered Antibody FC Regions and Uses Thereof |
| CN101273134B (zh) | 2005-07-27 | 2012-01-04 | 王庆华 | 用于预防和治疗ⅰ型和ⅱ型糖尿病的组合物和方法 |
| JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
| MX2009012343A (es) * | 2007-05-14 | 2010-02-10 | Biogen Idec Inc | Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello. |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| KR20100020516A (ko) | 2007-07-10 | 2010-02-22 | 일라이 릴리 앤드 캄파니 | Ｇｌｐ-1-ｆｃ 융합 단백질 제제 |
| MX2011006870A (es) * | 2008-12-23 | 2011-07-19 | Genentech Inc | Variantes de inmunoglobulina con union alterada a proteina a. |
| CA2754408A1 (en) | 2009-03-30 | 2010-10-14 | Boehringer Ingelheim International Gmbh | Fusion proteins comprising canine fc portions |
| WO2010117448A2 (en) | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| US20130108623A1 (en) | 2010-03-29 | 2013-05-02 | Zymeworks Inc | Antibodies with Enhanced or Suppressed Effector Function |
| JP2013537416A (ja) | 2010-08-13 | 2013-10-03 | メディミューン リミテッド | 変異型Ｆｃ領域を含むモノマーポリペプチド及び使用方法 |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| CA2835094C (en) * | 2011-05-06 | 2020-12-22 | David Gearing | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| SG10201500957QA (en) | 2011-05-06 | 2015-04-29 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| EP2537864B1 (en) * | 2011-06-24 | 2019-08-07 | Laboratoire Français du Fractionnement et des Biotechnologies | Fc variants with reduced effector functions |
| AU2012286048A1 (en) | 2011-07-18 | 2014-02-20 | Arts Biologics A/S | Long acting luteinizing hormone (LH) compound |
| CA2842067A1 (en) | 2011-07-19 | 2013-01-24 | The National Institute For Biotechnology In The Negev, Ltd. | Novel il-17r-ecd mutants |
| US9790280B2 (en) | 2011-10-26 | 2017-10-17 | Elanco Tiergesundheit Ag | Monoclonal canine CD20 antibodies and methods of use |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| KR102041412B1 (ko) * | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | 면역글로불린 Ｆｃ 단편 유도체 |
| JP2015509714A (ja) * | 2012-02-22 | 2015-04-02 | エヌヴィーアイピー プロプライエタリー リミテッド | 腫瘍壊死因子レセプター融合タンパク質及び前記タンパク質を使用する方法 |
| CA2871934C (en) | 2012-04-30 | 2023-06-13 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
| CA2879814A1 (en) | 2012-08-02 | 2014-02-06 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece |
| WO2014093387A1 (en) | 2012-12-10 | 2014-06-19 | Kindred Biosciences, Inc. | Vegf receptor fusion proteins for veterinary use |
| US9487587B2 (en) | 2013-03-05 | 2016-11-08 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof |
| EP3027647A4 (en) | 2013-07-31 | 2017-01-04 | Amgen Inc. | Stabilization of fc-containing polypeptides |
| WO2015022420A1 (en) | 2013-08-16 | 2015-02-19 | Medimmune Limited | Gip and glp-1 receptor dual-agonists for the treatment of diabetes |
| AU2014368453B2 (en) * | 2013-12-20 | 2020-04-16 | Intervet International B.V. | Caninized murine anti-canine PD-1 antibodies |
| EP3104887A4 (en) | 2014-02-11 | 2017-03-15 | Beijing Advaccine Biotechnology Co. Ltd. | Vaccines with interleukin-17 as an adjuvant |
| WO2016044189A1 (en) | 2014-09-15 | 2016-03-24 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists |
| ES2853823T3 (es) | 2014-09-30 | 2021-09-17 | Intervet Int Bv | Anticuerpos de PD-L1 que se unen a PD-L1 canino |
| RU2713131C1 (ru) | 2014-11-06 | 2020-02-03 | Ф. Хоффманн-Ля Рош Аг | ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМИ СВОЙСТВАМИ СВЯЗЫВАНИЯ FcRn И БЕЛКА А |
| KR101825048B1 (ko) | 2014-12-31 | 2018-02-05 | 주식회사 제넥신 | GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도 |
| MA53297A (fr) | 2015-03-23 | 2022-05-04 | Jounce Therapeutics Inc | Anticorps anti-icos |
| RU2728710C2 (ru) | 2015-10-19 | 2020-07-30 | Новартис Аг | Способы лечения нерентгенографического аксиального спондилоартрита, используя антагонисты интерлейкина-17 (il-17) |
| ES3014160T3 (en) | 2015-12-18 | 2025-04-21 | Intervet Int Bv | Caninized human antibodies to human and canine il-4r alpha |
| ES2871117T3 (es) | 2016-01-26 | 2021-10-28 | Defensin Therapeutics Aps | Procedimientos para modular la microbiota intestinal |
| CA3014461C (en) | 2016-02-18 | 2023-02-28 | Elanco Us Inc. | Chimeric canine anti-cd20 antibody |
| CN109844124B (zh) | 2016-05-20 | 2023-10-03 | 哈佛学院董事及会员团体 | 年龄相关疾病和病症的基因治疗方法 |
| EP3481413A4 (en) | 2016-07-08 | 2020-01-08 | Askgene Pharma, Inc. | FUSION PROTEIN WITH LEPTIN AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| EP3526246A1 (en) | 2016-10-17 | 2019-08-21 | Vetoquinol SA | Modified antibody constant region |
| WO2018102668A1 (en) | 2016-12-02 | 2018-06-07 | The Texas A&M University System | Fusion proteins for selectively depleting antigen-specific antibodies |
| JP7657548B2 (ja) * | 2017-04-21 | 2025-04-07 | エランコ・ユーエス・インコーポレイテッド | 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子 |
| WO2018236728A1 (en) | 2017-06-18 | 2018-12-27 | Kindred Biosciences, Inc. | ANTIBODIES AND ANTAGONISTS OF IL17A FOR VETERINARY USE |
| AU2018318440A1 (en) | 2017-08-15 | 2020-02-13 | Kindred Biosciences, Inc. | IgG Fc variants for veterinary use |
| HUE062719T2 (hu) | 2018-06-29 | 2023-11-28 | Akston Biosciences Corp | Ultra-hosszú hatású inzulin-FC fúziós fehérjék és az alkalmazási eljárások |
| JP2022500037A (ja) | 2018-09-14 | 2022-01-04 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学的使用のための抗ｉｌ４受容体抗体 |
| EP3866842A4 (en) | 2018-10-18 | 2022-07-13 | Kindred Biosciences, Inc. | FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE |
| EP3870601A4 (en) | 2018-10-25 | 2022-07-13 | Kindred Biosciences, Inc. | IL4/IL13 RECEPTOR MOLECULE FOR USE IN VETERINARY MEDICINE |
| WO2020116560A1 (ja) | 2018-12-05 | 2020-06-11 | 株式会社バイカ・セラピュティクス | 抗体のＦｃ領域改変体 |
| JP2022511882A (ja) | 2018-12-12 | 2022-02-01 | キンドレッド バイオサイエンシズ インコーポレイテッド | 獣医学的使用のためのエリスロポエチンアナログ |
| WO2020139984A1 (en) | 2018-12-27 | 2020-07-02 | Kindred Biosciences, Inc. | Igg fc variants for veterinary use |
| CN120005022A (zh) | 2019-01-03 | 2025-05-16 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物及使用方法 |
| KR20220066002A (ko) | 2019-03-20 | 2022-05-23 | 킨드레드 바이오사이언시스, 인코포레이티드 | 의학적 용도의 ngf 길항제 |
| JP7762645B2 (ja) | 2019-08-22 | 2025-10-30 | シダラ セラピューティクス インコーポレーテッド | バリアントｆｃドメイン及びその使用 |
| CN114364796B (zh) | 2019-09-02 | 2023-07-11 | 甘李药业股份有限公司 | 嵌合蛋白 |
| US11186623B2 (en) | 2019-12-24 | 2021-11-30 | Akston Bioscience Corporation | Ultra-long acting insulin-Fc fusion proteins and methods of use |
| IL297287A (en) | 2020-04-17 | 2022-12-01 | Zoetis Services Llc | Canine antibody variants |
| EP4136109A1 (en) | 2020-04-17 | 2023-02-22 | Zoetis Services LLC | Feline antibody variants |
| MX2022013149A (es) | 2020-04-22 | 2023-02-09 | Kindred Biosciences Inc | Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario. |
| CA3173864A1 (en) | 2020-04-22 | 2021-10-28 | Shyr Jiann Li | Long-acting anti-il31 antibodies for veterinary use |
| JP7832123B2 (ja) | 2020-05-11 | 2026-03-17 | インベテックス インコーポレイテッド | 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法 |
| EP4166574A4 (en) | 2020-06-10 | 2025-01-15 | Bica Therapeutics Inc. | FUSION PROTEIN WITH ERYTHROPOIETIN POLYPEPTIDE |
| EP4172193A1 (en) | 2020-06-29 | 2023-05-03 | Zoetis Services LLC | Feline antibody variants for improving stability |
| CN116096741B (zh) | 2020-07-10 | 2024-10-18 | 因外泰克斯公司 | 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法 |
| WO2022046941A1 (en) | 2020-08-26 | 2022-03-03 | Angiex, Inc. | Antimitotic tetrapeptide-antibody conjugates and methods of using same |
-
2018
- 2018-08-15 AU AU2018318440A patent/AU2018318440A1/en not_active Abandoned
- 2018-08-15 US US16/638,402 patent/US12297272B2/en active Active
- 2018-08-15 CN CN201880064650.9A patent/CN111182915A/zh active Pending
- 2018-08-15 KR KR1020267013181A patent/KR20260074394A/ko active Pending
- 2018-08-15 BR BR112020002871-1A patent/BR112020002871A2/pt unknown
- 2018-08-15 WO PCT/IB2018/056142 patent/WO2019035010A1/en not_active Ceased
- 2018-08-15 KR KR1020207005513A patent/KR102959451B1/ko active Active
- 2018-08-15 CA CA3071337A patent/CA3071337A1/en active Pending
- 2018-08-15 CN CN202411340586.6A patent/CN119390821A/zh active Pending
- 2018-08-15 JP JP2020507675A patent/JP2020531002A/ja active Pending
- 2018-08-15 EP EP18846242.8A patent/EP3668536A4/en active Pending
- 2018-08-15 MX MX2020001707A patent/MX2020001707A/es unknown
-
2023
- 2023-09-06 AU AU2023226676A patent/AU2023226676B2/en active Active
-
2025
- 2025-08-22 AU AU2025220819A patent/AU2025220819A1/en active Pending
- 2025-11-07 JP JP2025188214A patent/JP2026048634A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7748393B2 (ja) | Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法 | |
| US12351622B2 (en) | Modified product of Fc domain of antibody | |
| CN113038964B (zh) | 超长效胰岛素-fc融合蛋白及使用方法 | |
| US20210122805A1 (en) | Fc FUSION PROTEINS COMPRISING NOVEL LINKERS OR ARRANGEMENTS | |
| JP7231553B2 (ja) | Ｔｇｆ－ｂ－受容体外部ドメイン融合分子及びその使用 | |
| US10287336B2 (en) | Feline erythropoietin receptor agonists | |
| AU2006304846B2 (en) | Methods for generating monovalent IgG | |
| JP2017527272A5 (cg-RX-API-DMAC10.html) | ||
| US20130121959A1 (en) | Il-22-fc and hepcidin activity | |
| JP2019511457A5 (cg-RX-API-DMAC10.html) | ||
| WO2005097998A2 (en) | Il-18 specific polypeptides and therapeutic uses thereof | |
| TW202444759A (zh) | Ａβ靶向蛋白及使用方法 | |
| EP4166574A1 (en) | Fusion protein containing erythropoietin polypeptide | |
| US20260077054A1 (en) | Combinations of anti-gip antibodies and incretins and uses thereof |